MICROBIOTA-HOST INTERACTION MODELS IN THE INTESTINAL ENVIRONMENT AND ITS APPLICATION IN THE DEVELOPMENT OF PROBIOTIC AND PREBIOTIC PRODUCTS (Q3211304): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Created claim: summary (P836): THE USE OF PROBIOTICS AND PREBIOTICS TO MAINTAIN OR IMPROVE THE STATE OF HEALTH THROUGH THE MODULATION OF THE INTESTINAL MICROBIOTA IS AN ACTIVE FIELD OF RESEARCH. THE MAJORITY OF PROBIOTICS HAVE TRADITIONALLY BEEN SELECTED ACCORDING TO THEIR TECHNOLOGICAL PROPERTIES, HAVING SO FAR CARRIED OUT VERY FEW FUNCTIONAL STUDIES THAT TAKE INTO ACCOUNT THE SPECIFICITY OF THE INTERACTION OF EACH PROBIOTIC/PREBIOTICO WITH THE HOST AND THE DEEP EFFECT THAT...)
(‎Changed label, description and/or aliases in en: translated_label)
label / enlabel / en
 
MICROBIOTA-HOST INTERACTION MODELS IN THE INTESTINAL ENVIRONMENT AND ITS APPLICATION IN THE DEVELOPMENT OF PROBIOTIC AND PREBIOTIC PRODUCTS

Revision as of 11:08, 14 October 2021

Project Q3211304 in Spain
Language Label Description Also known as
English
MICROBIOTA-HOST INTERACTION MODELS IN THE INTESTINAL ENVIRONMENT AND ITS APPLICATION IN THE DEVELOPMENT OF PROBIOTIC AND PREBIOTIC PRODUCTS
Project Q3211304 in Spain

    Statements

    0 references
    164,560.0 Euro
    0 references
    205,700.0 Euro
    0 references
    80.0 percent
    0 references
    1 January 2014
    0 references
    31 December 2017
    0 references
    AGENCIA CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    0 references
    0 references

    43°28'52.79"N, 5°26'0.46"W
    0 references
    33076
    0 references
    LA UTILIZACION DE PROBIOTICOS Y PREBIOTICOS PARA MANTENER O MEJORAR EL ESTADO DE SALUD A TRAVES DE LA MODULACION DE LA MICROBIOTA INTESTINAL ES UN CAMPO ACTIVO DE INVESTIGACION. LA MAYORIA DE LOS PROBIOTICOS SE HAN SELECCIONADO TRADICIONALMENTE ATENDIENDO A SUS PROPIEDADES TECNOLOGICAS, HABIENDOSE REALIZADO HASTA EL MOMENTO MUY POCOS ESTUDIOS DE FUNCIONALIDAD QUE TENGAN EN CUENTA LA ESPECIFICIDAD DE LA INTERACCION DE CADA PROBIOTICO/PREBIOTICO CON EL HOSPEDADOR Y EL PROFUNDO EFECTO QUE LA MICROBIOTA INTESTINAL CIRCUNDANTE EJERCE SOBRE ESTA INTERACCION. UNA ALTERNATIVA ES LA SELECCION DE PROBIOTICOS Y PREBIOTICOS DESTINADOS A POBLACIONES HUMANAS ESPECIFICAS, CON UNA ELEVADA FUNCIONALIDAD QUE PERMITA SUPERAR LA EVALUACION QUE DEBEN REALIZAR LAS AUTORIDADES COMPETENTES, PREVIA A LA APROBACION DE ALEGACIONES DE PROPIEDADES SALUDABLES. PARA QUE ESTA APROXIMACION SEA FACTIBLE, SE REQUIERE EL DESARROLLO DE MODELOS DE ESTUDIO RAZONABLEMENTE SENCILLOS Y ECONOMICAMENTE ASEQUIBLES QUE TENGAN EN CUENTA LA COMPLEJIDAD DE LA MICROBIOTA INTESTINAL Y QUE TENGAN UNA ELEVADA CAPACIDAD PARA PREDECIR LA FUNCIONALIDAD IN VIVO DE PROBIOTICOS Y PREBIOTICOS, COMO PASO PREVIO A LOS COSTOSOS Y COMPLICADOS ESTUDIOS DE INTERVENCION CLINICA. _x000D_ POR ELLO, ESTE PROYECTO PLANTEA LA EVALUACION DE MODELOS DE INTERACCION MICROBIOTA/HOSPEDADOR EN EL ENTORNO INTESTINAL DE GRUPOS HUMANOS ESPECIFICOS (NIÑOS PREMATUROS, ANCIANOS, PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL, PACIENTES CON SINDROME DE COLON IRRITABLE Y EXCESIVA PRODUCCION DE GAS, Y EVENTUALMENTE ALGUNA POBLACION MAS DEPENDIENDO DE LA ACCESIBILIDAD A LAS MUESTRAS) QUE PERMITAN DETERMINAR LA FUNCIONALIDAD Y EFICACIA DE PROBIOTICOS Y PREBIOTICOS. EN PRIMER LUGAR PRETENDEMOS DETERMINAR EL EFECTO DE MICROBIOTAS INTESTINALES DE DIFERENTES GRUPOS POBLACIONALES SOBRE DISTINTOS PARAMETROS FISIOLOGICOS Y GENETICOS DE LA LINEA CELULAR INTESTINAL DE CARCINOMA HUMANO HT-29. EL EFECTO DE AQUELLAS MICROBIOTAS QUE MUESTREN DIFERENCIAS EN LOS MODELOS IN VITRO SE EVALUARAN EN MODELOS IN VIVO DE GUSANO CAENORHABDITIS ELEGANS Y MOSCA DROSOPHILA MELANOGASTER COLONIZADOS POR DICHAS MICROBIOTAS. SE ANALIZARA DE FORMA TRANSVERSAL LA COMPOSICION Y EL PERFIL DE ACIDOS GRASOS DE CADENA CORTA EN TODOS ESTOS ENSAYOS A FIN DE IDENTIFICAR ALTERACIONES FUNCIONALES DE LA MICROBIOTA DE LOS DISTINTOS GRUPOS HUMANOS ANALIZADOS. LOS MODELOS IN VITRO E IN VIVO QUE HAYAN PERMITIDO OBSERVAR DIFERENCIAS ENTRE MICROBIOTAS SE UTILIZARAN PARA DETERMINAR LA INFLUENCIA DE PROBIOTICOS Y PREBIOTICOS SOBRE LA RESPUESTA DEL HOSPEDADOR A LA MICROBIOTA INTESTINAL. COMO PROBIOTICOS SE ENSAYARAN PRINCIPALMENTE CEPAS MICROBIANAS DEL GENERO BIFIDOBACTERIUM PERO TAMBIEN DE OTROS GENEROS, DE ORIGEN HUMANO, OBTENIDAS POR NOSOTROS EN PROYECTOS PREVIOS Y QUE SE ENCUENTRAN EN LA COLECCION DEL GRUPO INVESTIGADOR EN EL IPLA. ADEMAS, SE INCLUIRAN PROBIOTICOS "NO CONVENCIONALES" Y "MICROBIOTAS SINTETICAS" IDENTIFICADAS A PARTIR DE LA COMPOSICION DE LAS MICROBIOTAS OBTENIDA EN LA PRIMERA PARTE DEL PROYECTO. ENTRE LOS PREBIOTICOS SE ENSAYARAN TANTO SUBSTRATOS COMERCIALES Y MEZCLAS DE ESTOS, COMO PREBIOTICOS NO COMERCIALES AISLADOS EN EL LABORATORIO POR OTROS GRUPOS DE INVESTIGACION, A LOS QUE PODAMOS TENER ACCESO. FINALMENTE, UNA SELECCION DE UNA/DOS CEPAS PROBIOTICAS Y/O PREBIOTICOS QUE MUESTREN MAYOR POTENCIAL MODULADOR EN LOS MODELOS ANTERIORES SE VALIDARAN EN RATONES BALB/C COMO PASO INICIAL DE LA CARACTERIZACION PRECLINICA. (Spanish)
    0 references
    THE USE OF PROBIOTICS AND PREBIOTICS TO MAINTAIN OR IMPROVE THE STATE OF HEALTH THROUGH THE MODULATION OF THE INTESTINAL MICROBIOTA IS AN ACTIVE FIELD OF RESEARCH. THE MAJORITY OF PROBIOTICS HAVE TRADITIONALLY BEEN SELECTED ACCORDING TO THEIR TECHNOLOGICAL PROPERTIES, HAVING SO FAR CARRIED OUT VERY FEW FUNCTIONAL STUDIES THAT TAKE INTO ACCOUNT THE SPECIFICITY OF THE INTERACTION OF EACH PROBIOTIC/PREBIOTICO WITH THE HOST AND THE DEEP EFFECT THAT THE SURROUNDING INTESTINAL MICROBIOTA EXERTS ON THIS INTERACTION. AN ALTERNATIVE IS THE SELECTION OF PROBIOTICS AND PREBIOTICS INTENDED FOR SPECIFIC HUMAN POPULATIONS, WITH A HIGH FUNCTIONALITY TO OVERCOME THE EVALUATION TO BE CARRIED OUT BY THE COMPETENT AUTHORITIES, PRIOR TO THE APPROVAL OF HEALTH CLAIMS. FOR THIS APPROACH TO BE FEASIBLE, THE DEVELOPMENT OF REASONABLY SIMPLE AND ECONOMICALLY AFFORDABLE STUDY MODELS THAT TAKE INTO ACCOUNT THE COMPLEXITY OF THE INTESTINAL MICROBIOTA AND HAVE A HIGH CAPACITY TO PREDICT THE IN VIVO FUNCTIONALITY OF PROBIOTICS AND PREBIOTICOS IS REQUIRED, AS A PRELIMINARY STEP TO THE COSTLY AND COMPLICATED CLINICAL INTERVENTION STUDIES. _x000D_ by ELLO, THIS PROJECT PLANTING THE EVALUATION OF MICROBIOTE INTERACTION MODEL/Hospital IN THE INTESTINAL ENVIRONMENT OF SPECIFIC HUMAN GROUPS (Children PREMATURES, ANCIANOS, PACIENTS WITH INTESTINAL INFLAMATORY DISEASE, PACIENTS WITH IRRITABLE COLON SYNDROME AND EXCESSIVE GAS PRODUCTIONAL PRODUCTION AND EVENTUALLY ANY POBLICATION MORE DEPENDING OF ACCESIBILITY TO THE MUSTRAS) who allow to deter the effectiveness and effectiveness of probiotic and prebiotic products. IN THE FIRST PLACE WE AIM TO DETERMINE THE EFFECT OF INTESTINAL MICROBIOTA OF DIFFERENT POPULATION GROUPS ON DIFFERENT PHYSIOLOGICAL AND GENETIC PARAMETERS OF THE INTESTINAL CELL LINE OF HUMAN CARCINOMA HT-29. THE EFFECT OF MICROBIOTA SHOWING DIFFERENCES IN IN VITRO MODELS WILL BE EVALUATED IN IN VIVO MODELS OF CAENORHABDITIS ELEGANS AND FLY DROSOPHILA MELANOGASTER COLONISED BY THESE MICROBIOTES. THE COMPOSITION AND PROFILE OF SHORT-CHAIN FATTY ACIDS WERE ANALYSED IN ALL THESE TRIALS IN ORDER TO IDENTIFY FUNCTIONAL ALTERATIONS OF THE MICROBIOTA OF THE DIFFERENT HUMAN GROUPS ANALYSED. IN VITRO AND IN VIVO MODELS THAT HAVE ALLOWED TO OBSERVE DIFFERENCES BETWEEN MICROBIOTES WILL BE USED TO DETERMINE THE INFLUENCE OF PROBIOTICS AND PREBIOTICOS ON HOST RESPONSE TO THE INTESTINAL MICROBIOTA. AS PROBIOTICS, MICROBIAL STRAINS OF THE BIFIDOBACTERIUM GENE ARE MAINLY REHEARSED, BUT ALSO FROM OTHER GENERA, OF HUMAN ORIGIN, OBTAINED BY US IN PREVIOUS PROJECTS AND FOUND IN THE COLLECTION OF THE RESEARCH GROUP IN IPLA. IN ADDITION, “UNCONVENTIONAL” PROBIOTICS AND “SYNTHETIC MICROBIOTES” IDENTIFIED FROM THE COMPOSITION OF THE MICROBIOTA OBTAINED IN THE FIRST PART OF THE PROJECT WILL BE INCLUDED. AMONG THE PREBIOTICS ARE TESTED BOTH COMMERCIAL SUBSTRATES AND MIXTURES OF THESE, AS WELL AS NON-COMMERCIAL PREBIOTICS ISOLATED IN THE LABORATORY BY OTHER RESEARCH GROUPS, TO WHICH WE CAN HAVE ACCESS. FINALLY, A SELECTION OF ONE/TWO PROBIOTIC STRAINS AND/OR PREBIOTICS THAT SHOW GREATER MODULATING POTENTIAL IN PREVIOUS MODELS WILL BE VALIDATED IN BALB/C MICE AS AN INITIAL STEP OF PRECLINIC CHARACTERISATION. (English)
    14 October 2021
    0 references
    Villaviciosa
    0 references

    Identifiers

    AGL2013-43770-R
    0 references